Description: Marvel Biotechnology Inc. operates in the biotechnology industry. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company targets neurological diseases that have not been treated with conventional therapeutics, such as Alzheimer's disease, depression, and addictions; lung cancer and fibrosis; and non-alcoholic steatohepatitis. Marvel Biotechnology Inc. was incorporated in 2018 and is based in Calgary, Canada.
Home Page: marvelbiotechnology.com
MRVL Technical Analysis
505 8th Avenue S.W.
Calgary,
AB
T2P 1G2
Canada
Phone:
403 770 2469
Officers
| Name | Title |
|---|---|
| Mr. J. Roderick Matheson | Pres, CEO & Exec. Chairman |
| Dr. Mark Williams M.B.A., Ph.D. | Chief Science Officer & Director |
| Mr. Harpreet Nijjar C.M.A., CPA | Chief Financial Officer |
| Ms. Jacqueline Groot | Corp. Sec. |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 29.5035 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |